| H01642 | |
| H number | H01642 |
| Name | Renal anemia |
| Description | Renal anemia is one of the most frequent complications of chronic kidney disease. Anemia leads to a decrease in oxygen delivery to vital organs, which is initially compensated for by tachycardia and cardiac hypertrophy, but eventually leads to the development of cardiovascular disease. Renal anemia is caused by the deficiency of endogenous erythropoietin (EPO) due to renal dysfunction. EPO is a glycoprotein hormone that has the role of the primary regulator of erythropoiesis. Formerly, treatment options were essentially limited to blood transfusions and androgen therapy, with its risks. However, since the late 1980s, the availability of recombinant human erythropoietin has revolutionized the management of renal anemia, and erythropoiesis-stimulating agents (ESAs) are now the mostly widely used drugs. |
| Category | Urinary system disease |
| Network | - |
| Gene | - |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Epoetin alfa [DR:D03231] Darbepoetin alfa [DR:D03651] Epoetin beta pegol [DR:D09998] Daprodustat [DR:D10874] |
| Comment | - |
| Other DBs | ICD-11: 3A71.2 ICD-10: N19 MeSH: D007676 |
| Reference | PMID:26381503 AUTHORS Mimura I, Tanaka T, Nangaku M TITLE How the Target Hemoglobin of Renal Anemia Should Be. JOURNAL Nephron 131:202-9 (2015) DOI:10.1159/000440849 PMID:16281953 AUTHORS Eckardt KU, Kurtz A TITLE Regulation of erythropoietin production. JOURNAL Eur J Clin Invest 35 Suppl 3:13-9 (2005) DOI:10.1111/j.1365-2362.2005.01525.x PMID:26456375 AUTHORS Kawahara K, Minakuchi J, Yokota N, Suekane H, Tsuchida K, Kawashima S TITLE Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. JOURNAL Nephrology (Carlton) 20 Suppl 4:29-32 (2015) DOI:10.1111/nep.12647 PMID:21930831 AUTHORS Locatelli F, Del Vecchio L TITLE Erythropoiesis-stimulating agents in renal medicine. JOURNAL Oncologist 16 Suppl 3:19-24 (2011) DOI:10.1634/theoncologist.2011-S3-19 |